

## **Andy Drechsler**

*Chief Financial Officer*



**Andy Drechsler** joined Altesa BioSciences as Chief Financial Officer (CFO) in April 2023. Andy offers over 25 years of financial and operational leadership experience in life sciences companies. From 2017 to 2021 Andy served as CFO of Provention Bio (Nasdaq:PRVB), a biopharmaceutical company focused on intercepting and preventing autoimmune diseases like type one diabetes. While at Provention, Andy helped grow the Company from 5 employees to over 80 employees, acquired three development stage programs, and raised over \$300 million in equity capital. Andy also served as CFO of Insmmed (Nasdaq: INSM) from 2012 to 2017. While at Insmmed, Andy helped raise over \$400 million via the equity capital markets, helped grow the company from 40 to over 160 people, and established an international infrastructure of six entities operating in the US and the EU. His prior CFO roles also include: VaxInnate Corporation, a privately held clinical-stage biotechnology company developing vaccines for infectious diseases and Valera Pharmaceuticals, a publicly traded company, where he completed an initial public offering in 2006 and ultimately helped negotiate the sale of the company to Indevus Pharmaceuticals in 2007. He has also served as controller for Abbott Laboratories' Point of Care Division, which was publicly-traded as i-STAT Corporation prior to being acquired by Abbott, and Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme (now Sanofi). Andy graduated magna cum laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey. Andy serves on the Board of Directors of Baudax Bio (Nasdaq: BXRX) and the JDRF NJ Metro Board of Directors.